基于胃癌分子标志物特征的个体化术后随访策略

Individualized postoperative follow-up strategy based on the molecular biomarker profiles of gastric cancer

  • 摘要: 胃癌根治术后复发是影响患者长期生存的关键因素。术后随访的核心目标包括早期发现无症状复发以改善预后,以及监测营养状态与远期并发症以维护整体健康。当前中国临床肿瘤学会、日本胃癌协会、美国国家综合癌症网络等指南虽提出基于病理学分期的随访方案,但在随访强度与方式上存在差异,且缺乏高级别循证医学证据。基于分子标志物的个体化随访策略正成为新方向,微卫星高度不稳定、Claudin 18.2、程序性死亡受体配体1、EB病毒、人表皮生长因子受体2、成纤维细胞生长因子受体2b、甲胎蛋白等分子亚型与胃癌的预后、复发模式及治疗不良反应存在一定关联,可在标准分期基础上为个体化随访调整提供参考;但现有证据多源于晚期人群的治疗和(或)预后研究,尚缺乏针对术后随访策略本身的高级别前瞻性验证。新型生物标志物如循环肿瘤DNA动态监测在预警微小残留病灶方面展现出一定优势,但受胃癌异质性影响,该辅助手段的诊断效能与假阳性问题仍待明确。老年胃癌患者需结合预期寿命与生命质量制订分层随访方案。笔者系统性探讨胃癌根治术后随访策略的优化路径及其对改善患者预后的重要意义。

     

    Abstract: Postoperative recurrence following radical gastrectomy is a critical determinant of long‑term survival in gastric cancer patients. The core objectives of postoperative surveillance include early detection of asymptomatic recurrence to improve prognosis, as well as monitoring of nutritional status and long‑term complications to preserve overall health. Although current guide-lines from Chinese Society of Clinical Oncology, Japan Gastric Cancer Association, National Compre-hensive Cancer Network of the United States, and other organizations have proposed pathological stage‑based follow‑up protocols, they differ in surveillance intensity and modality, and are largely lacking in high‑level medicine evidence‑based support. Individualized surveillance strategies based on molecular biomarkers are emerging as a new direction; molecular subtypes including microsate-llite instability‑high, Claudin 18.2, programmed death‑ligand 1, Epstein‑Barr virus, human epidermal growth factor receptor 2, fibroblast growth factor receptor 2 isoform b, and alpha‑fetoprotein have demonstrated certain associations with prognosis, recurrence patterns, and treatment‑related toxicities in gastric cancer, and may serve as supplementary references for individualized surveillance adjust-ments beyond standard staging. However, the existing evidence is predominantly derived from treatment/prognostic studies in advanced‑stage populations, and high‑level prospective validation specifically targeting postoperative surveillance strategies per se remains lacking. Dynamic monitoring of new biomarkers such as the circulating tumor DNA has shown potential advantages in the early warning of minimal residual disease; nevertheless, owing to the heterogeneity of gastric cancer, its diagnostic performance as a complementary monitoring tool and the issue of false positives remain to be clarified. For elderly patients of gastric cancer, a stratified surveillance plan should be developed with due consideration of life expectancy and quality of life. The authors systematically address the optimized pathways for postoperative surveillance strategies following radical gastrectomy for gastric cancer and their significance in improving patient prognosis.

     

/

返回文章
返回